GILDQ3 20261/5Estimate vs Actual
Earnings per Share
- Estimate
- $2.24
- Actual
- $2.55
+13.7% vs Estimate
Revenue
- Estimate
- $7.96 B
- Actual
- $8.30 B
+4.2% vs Estimate
Gilead Sciences Q3 2026 · Story
Read the quarter card by card, ready to share.
GILDQ3 20261/5GILDQ3 20262/5Guidance
Full-Year Product Sales
- Company Guidance
- 31.0 – 31.3 billion
- Market Estimate
- 30.77 billion
1.3% Above Estimate ▲
Product Sales ex-Veklury
- Company Guidance
- 30.7 – 31.0 billion
Raised 3.0% ▲
Full-Year Adjusted EPS
- Company Guidance
- -1.20 – -0.85 $
- Market Estimate
- -0.45 $
Midpoint Down $0.55 ▼
GILDQ3 20263/5Price Reaction
First Full Session
+ 3.1%
From the report-day close to the next session's close.
Post-Report Moves
- This Report+ 3.1%
- Aug 4− 2.6%
GILDQ3 20264/5In 30 Seconds
Revenue of $8.30B beat estimates by 6.4%, and adjusted EPS of $2.55 beat by 16.4%.
- HIV sales grew 18%; the company raised full-year product sales guidance to $31.0-31.3B.
- The stock rose 4.1% intraday; the 2028 Biktarvy price cut did not hold back the reaction.
First point of the analysis's “In 30 Seconds”.
Full AnalysisGILDQ3 20265/5Score
72/ 100
ViewBUY
Not Investment Advice